Ultra-early response assessment in lymphoma treatment: [18F]FDG PET/MR captures changes in glucose metabolism and cell density within the first 72 hours of treatment
Open Access
- 26 February 2018
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 45 (6) , 931-940
Abstract
Purpose To determine whether, in patients with Hodgkin lymphoma (HL) or non-Hodgkin lymphoma (NHL), [18F]FDG PET/MR can capture treatment effects within the first week after treatment initiation, and whether changes in glucose metabolism and cell density occur simultaneously. Methods Patients with histologically proven HL or NHL were included in this prospective IRB-approved study. Patients underwent [18F]FDG PET/MR before, and then 48–72 h after (follow-up 1, FU-1) and 1 week after (FU-2) initiation of the first cycle of their respective standard chemotherapy (for HL) or immunochemotherapy (for NHL). Standardized [18F]FDG uptake values (SUVmax, SUVmean) and apparent diffusion coefficients (ADCmin, ADCmean) based on diffusion-weighted MRI, and metabolic and morphological tumour volumes (MTV, VOL) were assessed at each time-point. Multilevel analyses with an unstructured covariance matrix, and pair-wise post-hoc tests were used to test for significant changes in SUVs, ADCs, MTVs and VOLs between the three time-points. Results A total of 58 patients (11 with HL and 47 with NHL) with 166 lesions were analysed. Lesion-based mean rates of change in SUVmax, SUVmean, ADCmin, ADCmean, MTV and VOL between baseline and FU-1 were −46.8%, −33.3%, +20.3%, +14%, −46% and −12.8%, respectively, and between baseline and FU-2 were −65.1%, −49%, +50.7%, +32.4%, −61.1% and −24.2%, respectively. These changes were statistically significant (P < 0.01) except for the change in VOL between baseline and FU-1 (P = 0.079). Conclusion In lymphoma patients, [18F]FDG PET/MR can capture treatment-induced changes in glucose metabolism and cell density as early as 48–72 h after treatment initiation.Keywords
Funding Information
- Medizinische Universität Wien
This publication has 37 references indexed in Scilit:
- An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmaxEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana LinfomiAnnals of Oncology, 2013
- Whole-body diffusion-weighted magnetic resonance imaging at 3 Tesla for early assessment of treatment response in non-Hodgkin lymphoma: a pilot studyCancer Imaging, 2013
- Whole-body diffusion magnetic resonance imaging in the assessment of lymphomaCancer Imaging, 2012
- SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphomaBlood, 2011
- Clinical Utility of PET/CT in LymphomaAmerican Journal of Roentgenology, 2010
- SUVmax in FDG-PET at the biopsy site correlates with the proliferation potential of tumor cells in non-Hodgkin lymphomaLeukemia & Lymphoma, 2009
- 18F-FDG Avidity in Lymphoma Readdressed: A Study of 766 PatientsJournal of Nuclear Medicine, 2009
- Early and Late Therapy Response Assessment With [18F]Fluorodeoxyglucose Positron Emission Tomography in Pediatric Hodgkin's Lymphoma: Analysis of a Prospective Multicenter TrialJournal of Clinical Oncology, 2009
- Phase II Study of Dose-Adjusted EPOCH and Rituximab in Untreated Diffuse Large B-Cell Lymphoma With Analysis of Germinal Center and Post-Germinal Center BiomarkersJournal of Clinical Oncology, 2008